Sponsors (22)
Official title: To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes.
Introduced September 4, 2025 by Christopher Henry Smith · Last progress September 4, 2025
The bill extends and modestly increases federal support to preserve and improve access to high‑quality cord‑blood/stem‑cell units for transplants, while giving HHS broader discretion that raises planning, consent, and representation risks and leaves actual funding dependent on future appropriations.
Patients who need cord‑blood or stem‑cell transplants and transplant centers will have federal program funding extended through FY2031 and the authorization level increased (to $33,009,000 annually for FY2027–2031), supporting continued transplant services, research, and planning.
Patients may get better access to clinically useful, high‑quality cord‑blood units because the Secretary can manage inventory to maximize available, clinically relevant units.
Transplant candidates and hospitals stand to benefit when units from nonoperational or noncompliant banks can be transferred and preserved for clinical use rather than lost due to bank closure or noncompliance.
Patients and hospitals may not see the intended funding increase if Congress does not appropriate the newly authorized amounts, because authorization does not guarantee appropriation.
State governments, cord‑blood banks, hospitals, and planners face increased uncertainty because the Secretary is given broad discretion (including replacing a numeric 'sufficient supply' target and expanded contracting/inventory authority), concentrating decision‑making in HHS and reducing predictability for collection and funding goals.
Donor communities with rare or less‑common cord‑blood types (including racial and ethnic minorities) risk underrepresentation if prioritization and inventory reductions use scientific/operational criteria without explicit protections.
Based on analysis of 3 sections of legislative text.
Reauthorizes and increases annual funding for the federal cell transplant and cord blood inventory programs through FY2031 and gives HHS new authority to manage inventory, quality, and transfers.
Reauthorizes and increases funding for the federal cell transplantation and national cord blood inventory programs through fiscal year 2031, updates inventory-management rules, and gives the Secretary of Health and Human Services greater flexibility to define sufficient supply and move units between banks. It also defines quality standards for cord blood units and requires the Secretary to use current scientific and clinical information when funding or contracting to maximize availability of high‑quality units. The bill preserves existing funding levels for 2022–2026 and adds a higher annual authorization for 2027–2031, clarifies program statutory language, and creates administrative authority to prioritize, transfer, and manage cord blood inventory to improve availability and quality for transplants and research.